(Q27688906)

English

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib (English)
0 references
Qinhua Huang
0 references
Ted W Johnson
0 references
Simon Bailey
0 references
Alexei Brooun
0 references
Kevin D Bunker
0 references
Benjamin J Burke
0 references
Michael R Collins
0 references
Andrew S Cook
0 references
J Jean Cui
0 references
Kevin N Dack
0 references
Judith G Deal
0 references
Ya-Li Deng
0 references
Dac Dinh
0 references
Lars D Engstrom
0 references
Mingying He
0 references
Jacqui Hoffman
0 references
Robert L Hoffman
0 references
Patrick S Johnson
0 references
Robert S Kania
0 references
Hieu Lam
0 references
Justine L Lam
0 references
Phuong T Le
0 references
Qiuhua Li
0 references
Laura Lingardo
0 references
Wei Liu
0 references
Melissa West Lu
0 references
Michele McTigue
0 references
Cynthia L Palmer
0 references
Paul F Richardson
0 references
Neal W Sach
0 references
Hong Shen
0 references
Tod Smeal
0 references
Graham L Smith
0 references
Albert E Stewart
0 references
Sergei Timofeevski
0 references
Konstantinos Tsaparikos
0 references
Hui Wang
0 references
Huichun Zhu
0 references
Jinjiang Zhu
0 references
Helen Y Zou
0 references
Martin P Edwards
0 references
27 February 2014
0 references
57
0 references
4
0 references
1170-87
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit